Acromegaly affects roughly 60 out of every million people, making it a certified rare disease. In practical terms, that means about 20,000 people in the United States are living with the condition at any given time. But newer data suggests the true number may be higher than previously thought, with a large French study finding a prevalence closer to 104 per million when researchers combed through a decade of national hospital records.
Incidence and Prevalence by the Numbers
Each year, between 3 and 11 new cases per million people are diagnosed worldwide. That translates to roughly 1,000 to 3,600 new diagnoses annually in the U.S. Some countries report higher rates: Iceland has documented 7.7 new cases per million per year, and Italian data suggest up to 6.9 per 100,000, which is substantially higher than the classic estimates.
The gap between older and newer figures likely reflects better detection rather than a true increase in the disease itself. As awareness grows among primary care doctors and diagnostic tools become more accessible, people who might have gone undiagnosed a generation ago are now being identified. The French nationwide study covering 2012 to 2021 identified nearly 8,000 adult patients and calculated an annual incidence of 0.76 per 100,000, reinforcing the idea that acromegaly may be roughly twice as common as textbooks have traditionally stated.
Why It Takes So Long to Diagnose
Part of the reason acromegaly seems rarer than it is comes down to how slowly it develops. The condition is caused by a noncancerous tumor on the pituitary gland that pumps out excess growth hormone. That extra growth hormone signals the liver to overproduce a substance called IGF-1, which drives gradual changes in bone, tissue, and metabolism. Because these changes happen over years, patients and even their doctors often don’t notice them until the disease is well established.
The average delay between the first symptoms and a formal diagnosis is 4.5 to 5 years, though some studies put it closer to 10 years. The typical age at diagnosis falls in the mid-to-late 40s. Younger patients, those diagnosed at age 40 or under, tend to have larger tumors and more hormonal disruption at the time of diagnosis, suggesting the disease may behave more aggressively when it starts earlier in life.
Who Gets Acromegaly
Acromegaly shows no strong preference for one sex over the other, and men and women are diagnosed at similar ages with similar delays. There are, however, some differences in how the disease presents. Men tend to have higher IGF-1 levels at diagnosis and are more likely to experience low sex hormone levels (hypogonadism), which affects about 54% of men compared to 26% of women.
About 95% of cases are sporadic, meaning they arise without any family history. The remaining 5% have an identifiable genetic component. A mutation in a gene called AIP accounts for a significant share of hereditary cases, appearing in roughly 50% of families where multiple members develop growth hormone-producing tumors. Among people who appear to have no family history, only about 4% carry an AIP mutation. Childhood-onset cases are a different story: nearly half of children and adolescents diagnosed with acromegaly or gigantism have a detectable genetic cause.
Health Risks That Come With It
Acromegaly’s rarity doesn’t diminish its seriousness. Prolonged exposure to excess growth hormone puts significant strain on the cardiovascular system. Between 22% and 77% of patients develop high blood pressure, and prediabetes or type 2 diabetes occurs in anywhere from 22% to 77% of cases, depending on how long the disease has been active and how elevated hormone levels are. Abnormal cholesterol levels affect up to 61% of patients. At diagnosis, about 18% already show thickening of the heart’s left ventricle, which can progress to a form of heart disease specific to acromegaly if left untreated.
These complications are the primary reason acromegaly shortens life expectancy when it goes uncontrolled. Historically, untreated patients faced a mortality rate two to three times higher than the general population.
How Treatment Changes the Outlook
The prognosis for acromegaly has improved dramatically with modern treatment. Patients whose hormone levels are brought back to normal after treatment have a standardized mortality ratio of 0.71, meaning their death rate is actually lower than that of the general population (likely because they receive close medical monitoring). By contrast, patients whose growth hormone remains elevated above 1 ng/mL after treatment have a 55% higher mortality risk than average.
There is a gray zone. Patients with growth hormone levels between 1 and 2.5 ng/mL, just slightly above the ideal target, show mortality rates statistically indistinguishable from the general population. This suggests that getting hormone levels close to normal, even if not perfectly suppressed, still confers a meaningful survival benefit. The key variable is how quickly the disease is caught and how effectively hormone levels are managed over the long term.
Rarer Than You Think, or More Common?
Acromegaly sits in an unusual position among rare diseases. Its official prevalence of 60 per million qualifies it as rare by any standard definition, yet population-level studies consistently suggest the actual number of affected people is higher. The years-long diagnostic delay means that at any given moment, a meaningful number of people are walking around with undiagnosed acromegaly, experiencing symptoms like joint pain, enlarged hands and feet, excessive sweating, and fatigue that get attributed to aging or other conditions.
If the French prevalence figure of 104 per million holds in other countries, the global burden of acromegaly could be roughly double what older estimates suggest. That still makes it rare in absolute terms, but it means the condition is far from vanishingly uncommon. For every person diagnosed, there may be another still waiting for answers.